Role of glucagon in protein catabolism

Purpose of review Glucagon is known as a key hormone in the control of glucose and amino acid metabolism. Critical illness is hallmarked by a profound alteration in glucose and amino acid metabolism, accompanied by muscle wasting and hypoaminoacidemia. Here we review novel insights in glucagon (patho)physiology and discuss the recently discovered role of glucagon in controlling amino acid metabolism during critical illness. Recent findings The role of glucagon in glucose metabolism is much more complex than originally anticipated, and glucagon has shown to be a key player in amino acid metabolism. During critical illness, the contribution of glucagon in bringing about hyperglycemia appeared to be quite limited, whereas increased glucagon availability seems to contribute importantly to the typical hypoaminoacidemia via stimulating hepatic amino acid breakdown, without affecting muscle wasting. Providing amino acids further increases hepatic amino acid breakdown, mediated by a further increase in glucagon. Summary Glucagon plays a crucial role in amino acid metabolism during critical illness, with an apparent feedback loop between glucagon and circulating amino acids. Indeed, elevated glucagon may, to a large extent, be responsible for the hypoaminoacidemia in the critically ill and infusing amino acids increases glucagon-driven amino acid breakdown in the liver. These novel insights further question the rationale for amino acid administration during critical illness.

[1]  G. Van den Berghe,et al.  Amino acid supplements in critically ill patients , 2017, Pharmacological research.

[2]  J. Holst,et al.  Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition , 2017, American journal of respiratory and critical care medicine.

[3]  G. Van den Berghe,et al.  The Role of Autophagy in Critical Illness-induced Liver Damage , 2017, Scientific Reports.

[4]  T. Lange,et al.  Early goal-directed nutrition versus standard of care in adult intensive care patients: the single-centre, randomised, outcome assessor-blinded EAT-ICU trial , 2017, Intensive Care Medicine.

[5]  J. Gunst Recovery from critical illness-induced organ failure: the role of autophagy , 2017, Critical Care.

[6]  G. Van den Berghe,et al.  Effect of early supplemental parenteral nutrition in the paediatric ICU: a preplanned observational study of post-randomisation treatments in the PEPaNIC trial. , 2017, The Lancet. Respiratory medicine.

[7]  J. Holst,et al.  Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis , 2017, Diabetes.

[8]  G. Berghe On the Neuroendocrinopathy of Critical Illness. Perspectives for Feeding and Novel Treatments. , 2016 .

[9]  L. Cynober,et al.  Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness , 2016, Current opinion in clinical nutrition and metabolic care.

[10]  G. Van den Berghe On the Neuroendocrinopathy of Critical Illness. Perspectives for Feeding and Novel Treatments. , 2016, American journal of respiratory and critical care medicine.

[11]  C. Cummins,et al.  Glucocorticoids and Metabolic Control. , 2016, Handbook of experimental pharmacology.

[12]  A. Scheen,et al.  Inhibiting or antagonizing glucagon: making progress in diabetes care , 2015, Diabetes, obesity & metabolism.

[13]  O. Fiehn,et al.  Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass. , 2015, Cell reports.

[14]  R. Bellomo,et al.  Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial , 2015, Intensive Care Medicine.

[15]  D. D’Alessio,et al.  Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. , 2015, Physiological reviews.

[16]  A. Groeneveld,et al.  Metabolic response to the stress of critical illness. , 2014, British journal of anaesthesia.

[17]  J. Holst,et al.  Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? , 2014, Diabetologia.

[18]  G. Van den Berghe,et al.  Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a subanalysis of the EPaNIC trial. , 2013, The Lancet. Respiratory medicine.

[19]  G. Van den Berghe,et al.  Impact of early parenteral nutrition on metabolism and kidney injury. , 2013, Journal of the American Society of Nephrology : JASN.

[20]  D. Cook,et al.  A randomized trial of glutamine and antioxidants in critically ill patients. , 2013, The New England journal of medicine.

[21]  G. Van den Berghe,et al.  Role of disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. , 2013, American journal of respiratory and critical care medicine.

[22]  G. Van den Berghe,et al.  Early parenteral nutrition evokes a phenotype of autophagy deficiency in liver and skeletal muscle of critically ill rabbits. , 2012, Endocrinology.

[23]  S. Bloom,et al.  Minireview: Glucagon in stress and energy homeostasis. , 2012, Endocrinology.

[24]  A. Cherrington,et al.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. , 2012, The Journal of clinical investigation.

[25]  N. Ozaki,et al.  Remodeling of Hepatic Metabolism and Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides , 2011, Diabetes.

[26]  P. Lefèbvre Early milestones in glucagon research , 2011, Diabetes, obesity & metabolism.

[27]  M. Tschöp,et al.  The metabolic actions of glucagon revisited , 2010, Nature Reviews Endocrinology.

[28]  Teresa Pearson,et al.  Glucagon as a Treatment of Severe Hypoglycemia , 2008, The Diabetes educator.

[29]  G. Shepherd Treatment of poisoning caused by β-adrenergic and calcium-channel blockers , 2006 .

[30]  J. Holst,et al.  Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice , 2006, Diabetes.

[31]  G. Shepherd Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[32]  The effect of intraportal and peripheral infusions of glucagon on insulin and glucose concentrations and glucose tolerance in normal man , 1977, Diabetologia.

[33]  Bei B. Zhang,et al.  Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.

[34]  W. Druml,et al.  Amino acid kinetics in patients with sepsis. , 2001, The American journal of clinical nutrition.

[35]  K. Nair,et al.  Evidence for a catabolic role of glucagon during an amino acid load. , 1996, The Journal of clinical investigation.

[36]  D. Wynick,et al.  Glucagonoma syndrome. , 1987, The American journal of medicine.

[37]  J. Holst,et al.  Glucagon Immunoneutralization in Diabetic Rats Normalizes Urea Synthesis and Decreases Nitrogen Wasting , 1992, Diabetes.

[38]  O. Owen,et al.  Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. , 1980, The Journal of clinical investigation.

[39]  L. Orci,et al.  THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.

[40]  S. Bloom,et al.  A glucagonoma syndrome. , 1974, Lancet.

[41]  J. B. Collip,et al.  Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report. , 1962, Canadian Medical Association journal.

[42]  O. Behrens,et al.  The Amino Acid Sequence of Glucagon. II. The Hydrolysis of Glucagon with Chymotrypsin , 1957 .